• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)

    2/14/23 4:01:15 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FWP alert in real time by email
    SC 13G/A 1 ea173546-13ga1rosetta1_for.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    Forward Pharma A/S

    (Name of Issuer)

     

    Ordinary Shares, nominal value DKK 0.01 per share

    (Title of Class of Securities)

     

    34986J 204

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
      
    ☐Rule 13d-1(c)
      
    ☒Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 2 of 10 Pages

     

    1  

    NAMES OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

     

    Rosetta Capital I, LP

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☒

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5

    SOLE VOTING POWER

     

    0 shares

      6

    SHARED VOTING POWER

     

    5,296,510 ordinary shares (See Item 4)

      7

    SOLE DISPOSITIVE POWER

     

    0 shares

      8

    SHARED DISPOSITIVE POWER

     

    5,296,510 ordinary shares (See Item 4)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,296,510 ordinary shares (See Item 4)

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (a) (See Item 4)

    12  

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

    (a) The percentage is calculated using 99,276,587 ordinary shares outstanding as disclosed in the Issuer’s notice of general meeting, filed with the Securities and Exchange Commission on May 5, 2022.

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 3 of 10 Pages

     

    1  

    NAMES OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

     

    BML General Partner Limited

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☒

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5

    SOLE VOTING POWER

     

    0 shares

      6

    SHARED VOTING POWER

     

    5,296,510 ordinary shares (See Item 4)

      7

    SOLE DISPOSITIVE POWER

     

    0 shares

      8

    SHARED DISPOSITIVE POWER

     

    5,296,510 ordinary shares (See Item 4)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,296,510 ordinary shares (See Item 4)

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (a) (See Item 4)

    12  

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO

     

    (a) The percentage is calculated using 99,276,587 ordinary shares outstanding as disclosed in the Issuer’s notice of general meeting, filed with the Securities and Exchange Commission on May 5, 2022.

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 4 of 10 Pages

     

    1  

    NAMES OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

     

    Rosetta Capital Limited

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☒

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5

    SOLE VOTING POWER

     

    0 shares

      6

    SHARED VOTING POWER

     

    5,296,510 ordinary shares (See Item 4)

      7

    SOLE DISPOSITIVE POWER

     

    0 shares

      8

    SHARED DISPOSITIVE POWER

     

    5,296,510 ordinary shares (See Item 4)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,296,510 ordinary shares (See Item 4)

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3% (a) (See Item 4)

    12  

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO

     

    (a) The percentage is calculated using 99,276,587 ordinary shares outstanding as disclosed in the Issuer’s notice of general meeting, filed with the Securities and Exchange Commission on May 5, 2022.  

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 5 of 10 Pages

     

    Item 1(a) Name of Issuer:

     

    Forward Pharma A/S (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    Østergade 24A, 1, 1100 Copenhagen K, Denmark

     

    Item 2(a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1(k) promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Act: Rosetta Capital I, LP (“Rosetta I”), BML General Partner Limited (“BML General”), and Rosetta Capital Limited (“Rosetta Capital” and together with BML General, the “Rosetta Entities”) (the Rosetta Entities together with Rosetta I, the “Reporting Persons”).

     

    Item 2(b) Address of Principal Business Office or, if none, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

      ● Rosetta Capital I, LP, c/o Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, DE 19808.

     

      ● BML General Partner Limited, c/o Rosetta Capital Limited, Rectory House Thame Road, Haddenham, Bucks, England, HP17 8DA.

     

      ●

    Rosetta Capital Limited, c/o Rosetta Capital Limited, Rectory House Thame Road, Haddenham, Bucks, England, HP17 8DA.

     

    Item 2(c) Citizenship:

     

    Rosetta I is a limited partnership organized under the laws of the State of Delaware.

     

    BML General and Rosetta Capital are each a private company limited by share capital and organized under the laws of the United Kingdom.

     

    Item 2(d) Title of Class of Securities:

     

    Ordinary Shares of the Issuer, nominal value DKK 0.01 per share (the “Ordinary Shares”).

     

    Item 2(e) CUSIP Number:

     

    34986J 204

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 6 of 10 Pages

     

    Item 3 If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

      (j) ☐ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

     

      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

       

    Not applicable.

     

    Item 4

    Ownership:

     

      (a) Amount beneficially owned as of the date hereof:

     

    (1) Rosetta I directly owns 5,296,510 Ordinary Shares, or approximately 5.3% of the total number of Ordinary Shares outstanding.

     

    (2) The Rosetta Entities control Rosetta I through their respective direct and indirect ownership of Rosetta I partnership units, and may be deemed to share beneficial ownership of the Ordinary Shares of the Issuer held by Rosetta I by virtue of their ability to collectively direct the decisions of Rosetta I.

     

    (3) Rosetta Capital, in its capacity as the general partner of BML General, which is the general partner of Rosetta I, has the ability to direct the investment decisions of BML General, including the power to direct the decisions of the BML General regarding the vote or disposition of securities directly held by Rosetta I; therefore, Rosetta Capital may be deemed to beneficially own the Ordinary Shares of the Issuer held by Rosetta I.

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 7 of 10 Pages

     

    By virtue of the relationships described above, each of the Reporting Persons, other than Rosetta I, may be deemed to have indirect beneficial ownership of 5,296,510 Ordinary Shares of the Issuer held by Rosetta I, or approximately 5.3% of the total number of Ordinary Shares outstanding.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the Ordinary Shares referred to herein for the purposes of Section 13(d) of the Act, or for any other purpose, and, except to the extent of its pecuniary interest, such beneficial ownership is expressly disclaimed by each Reporting Person other than Rosetta I.

     

      (b) Percent of class: See the responses to Item 11 on the attached cover pages.

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote: See the responses to Item 5 on the attached cover pages.

     

      (ii) shared power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.

     

      (iii) sole power to dispose or to direct the disposition of: See the responses to Item 7 on the attached cover pages.

     

      (iv) shared power to dispose or to direct the disposition of: See the responses to Item 8 on the attached cover pages.

     

     

    Each Reporting Person expressly disclaims any assertion or presumption that it and the other persons on whose behalf this Statement is filed constitute a “group” for the purposes of Sections 13(d) and 13(g) of the Act and the rules thereunder. The filing of this statement should not be construed to be an admission that any member of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) and 13(g) of the Act.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    Not Applicable.

     

    Item 6 Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    Not Applicable.

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 8 of 10 Pages

     

    Item 8 Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9 Notice of Dissolution of Group:

     

    Not Applicable.

     

    Item 10 Certification:

     

    Not Applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-1(c).

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 9 of 10 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Joint Filing Agreement listed on Exhibit 99.1 hereto.

     

    Dated: February 14, 2023.

     

      ROSETTA CAPITAL I, LP
         
      By: /s/ Michael Forer
      Name:  Michael Forer
      Its: Director of the General Partner
       
      BML GENERAL PARTNER LIMITED
         
      By: /s/ Michael Forer
      Name: Michael Forer
      Its: Director
       
      ROSETTA CAPITAL LIMITED
         
      By: /s/ Michael Forer
      Name: Michael Forer
      Its: Director

     

     

     

     

    CUSIP No. 34986J 204   13G   Page 10 of 10 Pages

     

    EXHIBIT INDEX

     

    Exhibit No.  
    99.1 Joint Filing Agreement dated as of February 14, 2023, by and among each of the Reporting Persons

     

     

     

     

    Get the next $FWP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FWP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FWP
    SEC Filings

    View All

    SEC Form EFFECT filed by Forward Pharma A/S

    EFFECT - Forward Pharma A/S (0001604924) (Filer)

    1/24/23 12:15:25 AM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Forward Pharma A/S

    POS AM - Forward Pharma A/S (0001604924) (Filer)

    1/20/23 4:40:31 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Forward Pharma A/S

    S-8 POS - Forward Pharma A/S (0001604924) (Filer)

    1/20/23 4:35:43 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

    COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("we" or "Forward"), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"),

    12/19/22 6:00:00 AM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

    COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("Forward" or the "Company"), today announced that the Enlarged Board of Appeal (the "EBA") of the European Patent Office (the "EPO") has denied Forward's petition for review (the "Petition") of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding ("Opposition Proceeding").The EBA's rejection of the Petition ends the Opposition Proceeding in favor of the opponents and represents an unsuccessful outcome of the Opposition Proceeding, resulting in no royalties being due to the Company from B

    12/6/22 2:00:00 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

    COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("we," "Forward" or the "Company" and, together with its subsidiaries, the "Group"), today reported consolidated financial results for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was $1.9 million, or $0.02 per share, versus a net loss of $6.4 million, or $0.07 per share, for the year ended December 31, 2020. Our research, development, general and administrative costs increased from $3.4 million for the year ended December 31, 2020 to $3.9 million for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was favorably impacted by a non

    4/8/22 5:25:00 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FWP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)

    SC 13G/A - Forward Pharma A/S (0001604924) (Subject)

    2/14/23 4:01:15 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Forward Pharma A/S

    SC 13G - Forward Pharma A/S (0001604924) (Subject)

    12/29/22 4:04:53 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)

    SC 13G/A - Forward Pharma A/S (0001604924) (Subject)

    2/14/22 12:59:14 PM ET
    $FWP
    Biotechnology: Pharmaceutical Preparations
    Health Care